Release Details
Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September
- Management participation in a fireside chat is scheduled at the
Wells Fargo Healthcare Conference onWednesday, September 6 th at8:30 a.m. ET taking place inBoston, MA. - Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on
Thursday, September 7 th at9:05 a.m. ET taking place inNew York, NY . - A company presentation is scheduled at Cantor Fitzgerald’s 3rd Annual Healthcare Conference on
Tuesday, September 26 th at8:35 a.m. ET taking place inNew York, NY .
The audio portion of the presentations will be available on the investors page of the
About
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:Patrick O'Brien Senior Vice President, Investor RelationsCoherus BioSciences, Inc. pobrien@coherus.com +1 (650) 649-3527